Verona Pharma share positive ensifentrine results in COPD
The trial consisted of 37 patients with moderate-to-severe COPD, who received a single dose of either the drug or a placebo.
Read More
Tag: DPI
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
- Survodutide delivers 16.6% weight loss in major phase 3 obesity trial
- Kahimmune Therapeutics signs collaboration agreement with Gustave Roussy
